Omthera Pharmaveuticals

  • Home
  • About Us
    • Company Overview
    • Senior Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Epanova
    • About Epanova
    • Pipeline
    • Disease Overview
    • Web Site Links
  • Clinical Trials
  • News & Events
    • Articles
    • Events
    • Press Releases
    • Presentations
  • Contact Us
 

Omthera Pharmaceuticals, Inc. is an emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia. Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease.

 

 

Omthera Pharmaceuticals Announces Positive Long Term Bioavailability Data Comparing Epanova™ to Lovaza®
Omthera Pharmaceuticals Completes Enrollment of Pivotal Phase III EVOLVE Trial for Epanova™ in Patients with Very High Triglycerides
Timothy J. Maines Joins Omthera Pharmaceuticals as Vice President of Quality

more news >

Epanova™ combined with a Statin in Patients with HypertRiglycerIdemia to Reduce Non-HDL CholesTerol (ESPRIT)
EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE)
Epanova™ Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation (ECLIPSE)...

Omthera Pharmaceuticals, Inc. to Present at Leerink Swaan 2012 Global Healthcare Conference and Citi 2012 Global Healthcare Conference
February 19 and February 29, 2012

 

 

 

 
  • Home
  • About Us
  • Epanova
  • Clinical Trials
  • Library
  • Media
  • Contact Us
 

Copyright 2011© Omthera Pharmaceuticals